Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment

Mary M. Sweeney, MS, PhD; Denis G. Antoine, MD; Leticia Nanda, MS, CRNP; Hélène Géniaux, PharmD; Michelle R. Lofwall, MD; George E. Bigelow, PhD; Annie Umbricht, MD

doi:10.5055/jom.2018.0526

Authors

Mary M. Sweeney, MS, PhD
Denis G. Antoine, MD
Leticia Nanda, MS, CRNP
Hélène Géniaux, PharmD
Michelle R. Lofwall, MD
George E. Bigelow, PhD
Annie Umbricht, MD

DOI:

https://doi.org/10.5055/jom.2018.0526

Keywords:

methadone, weight gain, BMI, hypertension, diabetes, hypercholesterolemia

Abstract

Objective: This study describes changes in weight and cardiovascular risk factors over time among individuals enrolled in methadone maintenance treatment for opioid use disorder. Demographic and clinical predictors of weight gain were also evaluated.

Design: This study was a retrospective chart review evaluating data over a period of 3 years.

Setting: Medical records of individuals enrolled in an academic research outpatient methadone maintenance treatment program were reviewed.

Patients: Seventy-four individuals who were admitted and retained in methadone maintenance treatment for at least 3 consecutive years were included.

Outcome measures: Annual weight was assessed by calculating body mass index (BMI). Changes over time in cardiovascular risk factors of hypertension, diabetes, and hypercholesterolemia were also assessed.

Results: The percentage of patients categorized as overweight, obese, or morbidly obese BMI increased from 42 percent (n = 31) at admission to 76 percent (n = 56), 82 percent (n = 61), and 88 percent (n = 65) at 1, 2, and 3 years post-admission, respectively. Hypertension, diabetes, and hypercholesterolemia also tended to increase following admission. BMI increases tended to be greater for those with a higher dose of methadone, as well as for females and Black/African American individuals. No other predictors of weight gain were identified.

Conclusions: These data indicate that methadone maintenance treatment is associated with clinically meaningful weight gain and increases in cardiovascular risk factors. Given the importance of methadone maintenance for treatment of opioid use disorder, future research should examine additional predictors and potential mechanisms of weight gain among methadone patients and develop tailored interventions including nutritional knowledge and lifestyle recommendations.

Author Biographies

Mary M. Sweeney, MS, PhD

Instructor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Denis G. Antoine, MD

Assistant Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Leticia Nanda, MS, CRNP

Adult Nurse Practitioner, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Hélène Géniaux, PharmD

Pharmacist, Department of Toxicology and Pharmacovigilance, University Hospital of Limoges, Limoges, France

Michelle R. Lofwall, MD

Associate Professor, Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Psychiatry, University of Kentucky College of Medicine, Lexington, Kentucky

George E. Bigelow, PhD

Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Annie Umbricht, MD

Assistant Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

References

Ahrnsbrak R, Bose J, Hedden SL, et al.: Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2017.

Hedegaard H, Warner M, Minino AM: Drug overdose deaths in the United States, 1999-2016. NCHS Data Brief No. 294. Hyattsville, MD: National Center for Health Statistics, 2017: 1-8.

Park-Lee E, Lipari RN, Hedden SL, et al.: Receipt of services for substance use and mental health issues among adults: Results from the 2016 National Survey on Drug Use and Health. NSDUH Data Review. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017.

Brady KT, McCauley JL, Back SE: Prescription opioid misuse, abuse, and treatment in the United States: An update. Am J Psychiatry. 2016; 173 (1): 18-26.

Connery HS: Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harv Rev Psychiatry. 2015; 23 (2): 63-75.

Schuckit MA: Treatment of opioid-use disorders. N Engl J Med. 2016; 375 (4): 357-368.

Stotts AL, Dodrill CL, Kosten TR: Opioid dependence treatment: Options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10 (11): 1727-1740.

Veilleux JC, Colvin PJ, Anderson J, et al.: A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010; 30 (2): 155-166.

Mattick RP, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; (2): CD002207.

Sordo L, Barrio G, Bravo MJ, et al.: Mortality risk during and after opioid substitution treatment: Systematic review and metaanalysis of cohort studies. BMJ. 2017; 357: j1550.

Fenn JM, Laurent JS, Sigmon SC: Increases in body mass index following initiation of methadone treatment. J Subst Abuse Treat. 2015; 51: 59-63.

Gahr M, Eller J, Cabanis M, et al.: Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. J Subst Abuse Treat. 2017; 74: 7-15.

Mysels DJ, Vosburg SK, Benga I, et al.: Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients. J Opioid Manag. 2011; 7 (1): 47-53.

Parvaresh N, Sabahi AR, Mazhari S, et al.: A study of the sexual function, sleep, and weight status of patients after 6 months of methadone maintenance treatment. Addict Health. 2015; 7 (1-2): 24-29.

Peles E, Schreiber S, Sason A, et al.: Risk factors for weight gain during methadone maintenance treatment. Subst Abuse. 2016; 37 (4): 613-618.

Peles E, Schreiber S, Hamburger RB, et al.: No change of sleep after 6 and 12 months of methadone maintenance treatment . J Addict Med. 2011; 5 (2): 141-147.

GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al.: Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377 (1): 13-27.

Sason A, Adelson M, Herzman-Harari S, et al.: Knowledge about nutrition, eating habits and weight reduction intervention among methadone maintenance treatment patients. J Subst Abuse Treat. 2018; 86: 52-59.

Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation. 2003; 108 (4): 414-419.

National Center for Health Statistics: Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville, MD: National Center for Health Statistics, 2017.

Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee: Prevention, detection, evaluation, and management of high blood pressure in adults: Synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168 (5): 351-358.

Mysels DJ, Sullivan MA: The relationship between opioid and sugar intake: Review of evidence and clinical applications. J Opioid Manag. 2010; 6 (6): 445-452.

Sigmon SC: Additive burdens of malnutrition, poverty, and substance abuse. Lancet. 2016; 388 (10054): 1879-1880.

Alves D, Costa AF, Custódio D, et al.: Housing and employment situation, body mass index and dietary habits of heroin addicts in methadone maintenance treatment. Heroin Addict Relat Clin Probl. 2011; 13 (1): 11-14.

Nolan LJ, Scagnelli LM: Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007; 42 (10): 1555-1566.

Zador D, Lyons Wall PM, Webster I: High sugar intake in a group of women on methadone maintenance in South Western Sydney, Australia. Addiction. 1996; 91 (7): 1053-1061.